METIS TECHBIO-P Surges Again, Up Over 20% in Five Sessions Following AI Drug Development Alliance

Stock News06-17

Shares of METIS TECHBIO-P (07666) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days, pushing its total market capitalization beyond HK$170 billion.

The upward momentum follows the company's recent announcement of a strategic alliance with Deerfield, a leading global health investment and innovation platform. This partnership aims to deeply integrate METIS TECHBIO-P's proprietary technologies in AI-driven protein engineering, in vivo immunotherapies, and programmable biologics with Deerfield's extensive industry expertise and capabilities in translational medicine, clinical development, healthcare innovation, and global collaboration.

As part of this alliance, Deerfield will engage in deep collaboration with METIS TECHBIO-P on the global clinical development and commercial expansion of the company's self-developed AI-enabled nano-delivery platform, NanoForge, along with its related solutions and core pipeline projects. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's proprietary AiProtein platform.

Deerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137258067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137258067","market":"hk","top_or_hot":-1,"title":"METIS TECHBIO-P Surges Again, Up Over 20% in Five Sessions Following AI Drug Development Alliance","media":"Stock News","content":"<p>Shares of <b>METIS TECHBIO-P</b> (<b>07666</b>) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days, pushing its total market capitalization beyond HK$170 billion.<br><br>\nThe upward momentum follows the company's recent announcement of a strategic alliance with Deerfield, a leading global health investment and innovation platform. This partnership aims to deeply integrate METIS TECHBIO-P's proprietary technologies in AI-driven protein engineering, in vivo immunotherapies, and programmable biologics with Deerfield's extensive industry expertise and capabilities in translational medicine, clinical development, healthcare innovation, and global collaboration.<br><br>\nAs part of this alliance, Deerfield will engage in deep collaboration with METIS TECHBIO-P on the global clinical development and commercial expansion of the company's self-developed AI-enabled nano-delivery platform, NanoForge, along with its related solutions and core pipeline projects. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's proprietary AiProtein platform.<br><br>\nDeerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Surges Again, Up Over 20% in Five Sessions Following AI Drug Development Alliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Surges Again, Up Over 20% in Five Sessions Following AI Drug Development Alliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-17 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>METIS TECHBIO-P</b> (<b>07666</b>) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days, pushing its total market capitalization beyond HK$170 billion.<br><br>\nThe upward momentum follows the company's recent announcement of a strategic alliance with Deerfield, a leading global health investment and innovation platform. This partnership aims to deeply integrate METIS TECHBIO-P's proprietary technologies in AI-driven protein engineering, in vivo immunotherapies, and programmable biologics with Deerfield's extensive industry expertise and capabilities in translational medicine, clinical development, healthcare innovation, and global collaboration.<br><br>\nAs part of this alliance, Deerfield will engage in deep collaboration with METIS TECHBIO-P on the global clinical development and commercial expansion of the company's self-developed AI-enabled nano-delivery platform, NanoForge, along with its related solutions and core pipeline projects. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's proprietary AiProtein platform.<br><br>\nDeerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGIX","symbol_name":"通用人工智能 ETF-AGIX","start_time":0,"source_url":"","article_id":"1137258067","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137258067","pubTimestamp":1781675065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of METIS TECHBIO-P (07666) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGIX":"通用人工智能 ETF-AGIX","VXUS":"国际股票ETF-Vanguard","AIPO":"Defiance AI and Power Infrastructure ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","07666":"剂泰科技-P","BK4588":"碎股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"METIS TECHBIO-P再度大涨，继AI药物开发联盟后五个交易日涨超20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":1,"ARTY":1,"VXUS":1,"07666":1,"AGIX":1,"CHAT":1},"content_text":"Shares of METIS TECHBIO-P (07666) extended their recent gains, rising over 3% during the trading session. The stock has now accumulated an increase of more than 20% over the past five trading days, pushing its total market capitalization beyond HK$170 billion.\nThe upward momentum follows the company's recent announcement of a strategic alliance with Deerfield, a leading global health investment and innovation platform. This partnership aims to deeply integrate METIS TECHBIO-P's proprietary technologies in AI-driven protein engineering, in vivo immunotherapies, and programmable biologics with Deerfield's extensive industry expertise and capabilities in translational medicine, clinical development, healthcare innovation, and global collaboration.\nAs part of this alliance, Deerfield will engage in deep collaboration with METIS TECHBIO-P on the global clinical development and commercial expansion of the company's self-developed AI-enabled nano-delivery platform, NanoForge, along with its related solutions and core pipeline projects. This includes a leading T-cell engager (TCE) project discovered and advanced to the pre-clinical candidate stage by METIS TECHBIO-P's proprietary AiProtein platform.\nDeerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137258067","isCrawlerRequest":true}